Please assess the completion status of the following clinical trial:

Trial Title: Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males: Ages: 12 - less than 18 years.~* Bone age less than 14 ½ years at study initiation.~* Presence of puberty.~* Idiopathic short stature will be defined as a short child equal or less than -2SD for height, with normal GH responses to stimuli (\> or = 5ng/ml to at least 2 secretagogues) or a normal IGF-I and BP-3, normal body proportions and no other identifiable growth pathology.~* Accurate growth data for at least 6 months at baseline is available.~Exclusion Criteria:~* Chronic illnesses.~* Chronic use of glucocorticosteroids.~* Previous use of hormonal treatment with AIs, sex steroids or GH in the preceding 6 months.~* Birth weight small for gestational age (SGA).

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Aromatase Inhibitor (Type: ACTIVE_COMPARATOR): Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
- Growth Hormone (Type: ACTIVE_COMPARATOR): Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
- Aromatase Inhibitor and Growth Hormone (Type: ACTIVE_COMPARATOR): Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years

Based on this trial design, predict the completion outcome and termination type (if applicable).